Entasis therapeutics

Entasis Therapeutics: Revolutionizing Antibacterial Therapy

Entasis Therapeutics is a leading biopharmaceutical company that is dedicated to addressing the critical threat of multi-drug resistant bacteria. The company has assembled a world-class team of experts with a global calling to develop life-saving, long-lasting antibacterial therapies.

The rise of antibiotic-resistant bacteria has become one of the most pressing public health concerns in recent years. Traditional antibiotics are becoming less effective, and new drugs are urgently needed to combat these deadly infections. Entasis Therapeutics is at the forefront of this fight, developing innovative solutions that can help save lives and improve global health outcomes.

At Entasis Therapeutics, we believe that our mission goes beyond simply developing new drugs. We are committed to advancing the field of antibacterial therapy as a whole, by conducting cutting-edge research and collaborating with other experts in the field. Our goal is not just to create effective treatments for bacterial infections but also to contribute to a broader understanding of how these pathogens work and how they can be defeated.

One key area where Entasis Therapeutics excels is in its focus on multi-drug resistant bacteria (MDR). These strains have evolved resistance mechanisms that make them impervious to many traditional antibiotics, leaving patients vulnerable and healthcare providers struggling for solutions. By targeting MDR pathogens specifically, we hope to make significant strides towards reducing their impact on human health.

Our approach involves using advanced technologies such as genomics and proteomics to identify novel targets for drug development. We then use our expertise in medicinal chemistry and pharmacology to design compounds that can effectively target these targets while minimizing side effects on healthy cells.

One example of our success in this area is our lead product candidate ETX2514SUL/ETX2514CRBL (sulbactam-durlobactam), which has shown promising results against several MDR Gram-negative bacterial species including Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae (KPC) strains among others.

In addition to its focus on MDR pathogens, Entasis Therapeutics also works on other areas such as urinary tract infections (UTIs) caused by Escherichia coli or Klebsiella pneumoniae among others which affect millions worldwide every year causing significant morbidity especially among women population globally.

Another key aspect of our work at Entasis Therapeutics involves collaboration with other organizations across academia and industry sectors alike who share similar goals towards combating antibiotic resistance globally through various initiatives like CARB-X etc., which provides funding support for early-stage research projects focused on developing new antibacterial agents against priority pathogens identified by WHO's Global Priority List (GPL).

Overall, Entasis therapeutics' commitment towards revolutionizing antibacterial therapy through innovative approaches combined with strong collaborations makes it an ideal partner for anyone looking forward towards contributing positively towards global public health outcomes while addressing one of the most pressing challenges facing humanity today - antibiotic resistance!